Search Results | Blood | American Society of Hematology

1-20 of 47

2 3

Sort by

Sort Order Select

Journal Articles

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot

Blood (2022) 140 (Supplement 1): 12066–12067.

DOI: https://doi.org/10.1182/blood-2022-158042

Published: 2022

Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad

Blood (2022) 140 (Supplement 1): 6455–6457.

DOI: https://doi.org/10.1182/blood-2022-159585

Published: 2022

Journal Articles

Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Yuta Ito, Amira Marouf, Yasunori Kogure, Junji Koya, Mariko Tabata, Yuki Saito, Sumito Shingaki, Mitsuhiro Yuasa, Kentaro Yamaguchi, Julie Bruneau, Manon Vavasseur, Michaël Dussiot, Isabelle Andre, Akshay Joshi, Chantal Lagresle-Peyrou, Aude Magerus, Sammara Chaubard, David Lavergne, Emmanuel Bachy, Erika Brunet, Virginie Fataccioli, Chantal Brouzes, Camille Laurent, Laurence De Leval, Alexandra Traverse-Glehen, Céline Bossard, Marie Parrens, Véronique Meignin, Laure Philippe, Julien Rossignol, Felipe Suarez, Jean-Marie Michot, Olivier Tournilhac, Christine Bole-Feysot, Patrick Nitschke, Bruno Tesson, Cécile Laurent, Thierry Jo Molina, Vahid Asnafi, Sachiko Tsukita, Koji Izutsu, Hiroaki Miyoshi, Seiji Sakata, Akito Dobashi, Kengo Takeuchi, Koichi Ohshima, Philippe Gaulard, Arnaud Jaccard, Seishi Ogawa, Olivier Hermine, Keisuke Kataoka, Lucile Couronne

Blood (2022) 140 (Supplement 1): 1737–1739.

DOI: https://doi.org/10.1182/blood-2022-159869

Published: 2022

Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood (2022) 140 (Supplement 1): 9470–9472.

DOI: https://doi.org/10.1182/blood-2022-159586

Published: 2022

Journal Articles

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

Krish Patel, Jean-Marie Michot, Asher Chanan-Khan, Herve Ghesquieres, Kamal Bouabdallah, John C. Byrd, Guillaume Cartron, Craig A. Portell, Melhem Solh, Hervé Tilly, William G. Wierda, Patricia McGovern, Chelsea Johnson, Raman Garcha, Vincent Ribrag, Gabriel Brisou, David Liebowitz, Tycel Phillips

Blood (2021) 138 (Supplement 1): 2494.

DOI: https://doi.org/10.1182/blood-2021-144350

Published: 2021

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

DOI: https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Cyril Quivoron, Helene Lecourt, Jean-Marie Michot, Julien Lazarovici, Julien Rossignol, David Ghez, Veronique Vergé, Veronique Saada, Alina Danu, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 3763.

DOI: https://doi.org/10.1182/blood-2021-149369

Published: 2021

Journal Articles

Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma

Vincent Ribrag, Jean-Marie Michot, Lara Igleias, Daniel Tan, Brigette Ma, Matteo Duca, Zev A. Wainberg, Yu Yun Fan, Naoka Suenaga, Yi Cheng, Clinton Lai, Tomoya Yokota

Blood (2021) 138 (Supplement 1): 1422.

DOI: https://doi.org/10.1182/blood-2021-147904

Published: 2021

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

DOI: https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

DOI: https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD

Blood (2019) 134 (Supplement_1): 4079.

DOI: https://doi.org/10.1182/blood-2019-128564

Published: 2019

Journal Articles

Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies

Blood (2018) 132 (Supplement 1): 2412.

DOI: https://doi.org/10.1182/blood-2018-99-110875

Published: 2018

Journal Articles

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Blood (2018) 132 (Supplement 1): 1627.

DOI: https://doi.org/10.1182/blood-2018-99-118204

Published: 2018

Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4191.

DOI: https://doi.org/10.1182/blood-2018-99-113193

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

DOI: https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Shailaja Uttamsingh, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 449.

DOI: https://doi.org/10.1182/blood-2018-99-110213

Published: 2018

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

DOI: https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

DOI: https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

2 3

NARROW

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only